Myostatin (GDF-8) as a key factor linking muscle mass and bone structure

Moataz N. Elkasrawy, Mark W Hamrick

Research output: Contribution to journalReview article

111 Citations (Scopus)

Abstract

Myostatin (GDF-8) is a member of the transforming growth factor-beta (TGF-β) superfamily that is highly expressed in skeletal muscle, and myostatin loss-of-function leads to doubling of skeletal muscle mass. Myostatin-deficient mice have been used as a model for studying muscle-bone interactions, and here we review the skeletal phenotype associated with altered myostatin signaling. It is now known that myostatin is a key regulator of mesenchymal stem cell proliferation and differentiation, and mice lacking the myostatin gene show decreased body fat and a generalized increase in bone density and strength. The increase in bone density is observed in most anatomical regions, including the limbs, spine, and jaw, and myostatin inhibitors have been observed to significantly increase bone formation. Myostatin is also expressed in the early phases of fracture healing, and myostatin deficiency leads to increased fracture callus size and strength. Together, these data suggest that myostatin has direct effects on the proliferation and differentiation of osteoprogenitor cells, and that myostatin antagonists and inhibitors are likely to enhance both muscle mass and bone strength.

Original languageEnglish (US)
Pages (from-to)56-63
Number of pages8
JournalJournal of Musculoskeletal Neuronal Interactions
Volume10
Issue number1
StatePublished - Mar 1 2010

Fingerprint

Myostatin
Bone and Bones
Muscles
Bone Density
Cell Differentiation
Skeletal Muscle
Fracture Healing
Bony Callus
Jaw
Mesenchymal Stromal Cells
Osteogenesis
Transforming Growth Factor beta
Adipose Tissue

Keywords

  • ActRIIB
  • Bone density
  • GDF-8
  • Hypertrophy
  • Muscle-bone interactions

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Orthopedics and Sports Medicine

Cite this

Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. / Elkasrawy, Moataz N.; Hamrick, Mark W.

In: Journal of Musculoskeletal Neuronal Interactions, Vol. 10, No. 1, 01.03.2010, p. 56-63.

Research output: Contribution to journalReview article

@article{1b2a949ec35b4bda873a38be7989f944,
title = "Myostatin (GDF-8) as a key factor linking muscle mass and bone structure",
abstract = "Myostatin (GDF-8) is a member of the transforming growth factor-beta (TGF-β) superfamily that is highly expressed in skeletal muscle, and myostatin loss-of-function leads to doubling of skeletal muscle mass. Myostatin-deficient mice have been used as a model for studying muscle-bone interactions, and here we review the skeletal phenotype associated with altered myostatin signaling. It is now known that myostatin is a key regulator of mesenchymal stem cell proliferation and differentiation, and mice lacking the myostatin gene show decreased body fat and a generalized increase in bone density and strength. The increase in bone density is observed in most anatomical regions, including the limbs, spine, and jaw, and myostatin inhibitors have been observed to significantly increase bone formation. Myostatin is also expressed in the early phases of fracture healing, and myostatin deficiency leads to increased fracture callus size and strength. Together, these data suggest that myostatin has direct effects on the proliferation and differentiation of osteoprogenitor cells, and that myostatin antagonists and inhibitors are likely to enhance both muscle mass and bone strength.",
keywords = "ActRIIB, Bone density, GDF-8, Hypertrophy, Muscle-bone interactions",
author = "Elkasrawy, {Moataz N.} and Hamrick, {Mark W}",
year = "2010",
month = "3",
day = "1",
language = "English (US)",
volume = "10",
pages = "56--63",
journal = "Journal of Musculoskeletal Neuronal Interactions",
issn = "1108-7161",
publisher = "International Society of Musculoskeletal and Neuronal Interactions",
number = "1",

}

TY - JOUR

T1 - Myostatin (GDF-8) as a key factor linking muscle mass and bone structure

AU - Elkasrawy, Moataz N.

AU - Hamrick, Mark W

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Myostatin (GDF-8) is a member of the transforming growth factor-beta (TGF-β) superfamily that is highly expressed in skeletal muscle, and myostatin loss-of-function leads to doubling of skeletal muscle mass. Myostatin-deficient mice have been used as a model for studying muscle-bone interactions, and here we review the skeletal phenotype associated with altered myostatin signaling. It is now known that myostatin is a key regulator of mesenchymal stem cell proliferation and differentiation, and mice lacking the myostatin gene show decreased body fat and a generalized increase in bone density and strength. The increase in bone density is observed in most anatomical regions, including the limbs, spine, and jaw, and myostatin inhibitors have been observed to significantly increase bone formation. Myostatin is also expressed in the early phases of fracture healing, and myostatin deficiency leads to increased fracture callus size and strength. Together, these data suggest that myostatin has direct effects on the proliferation and differentiation of osteoprogenitor cells, and that myostatin antagonists and inhibitors are likely to enhance both muscle mass and bone strength.

AB - Myostatin (GDF-8) is a member of the transforming growth factor-beta (TGF-β) superfamily that is highly expressed in skeletal muscle, and myostatin loss-of-function leads to doubling of skeletal muscle mass. Myostatin-deficient mice have been used as a model for studying muscle-bone interactions, and here we review the skeletal phenotype associated with altered myostatin signaling. It is now known that myostatin is a key regulator of mesenchymal stem cell proliferation and differentiation, and mice lacking the myostatin gene show decreased body fat and a generalized increase in bone density and strength. The increase in bone density is observed in most anatomical regions, including the limbs, spine, and jaw, and myostatin inhibitors have been observed to significantly increase bone formation. Myostatin is also expressed in the early phases of fracture healing, and myostatin deficiency leads to increased fracture callus size and strength. Together, these data suggest that myostatin has direct effects on the proliferation and differentiation of osteoprogenitor cells, and that myostatin antagonists and inhibitors are likely to enhance both muscle mass and bone strength.

KW - ActRIIB

KW - Bone density

KW - GDF-8

KW - Hypertrophy

KW - Muscle-bone interactions

UR - http://www.scopus.com/inward/record.url?scp=77649198629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649198629&partnerID=8YFLogxK

M3 - Review article

VL - 10

SP - 56

EP - 63

JO - Journal of Musculoskeletal Neuronal Interactions

JF - Journal of Musculoskeletal Neuronal Interactions

SN - 1108-7161

IS - 1

ER -